AT-527
- Generic Name
- AT-527
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 2241337-84-6
- Unique Ingredient Identifier
- DAI4WL7JQ6
- Associated Conditions
- -
- Associated Therapies
- -
Study of AT-527 in Subjects With Normal and Impaired Renal Function
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05618314
- Locations
- 🇨🇦
Atea Study Site, Québec, Canada
Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT05256732
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Quebec, Canada
Bronchopulmonary PK of AT-527 (R07496998)
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04877769
- Locations
- 🇬🇧
Atea Study Site, London, United Kingdom
Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT04709835
- Locations
- 🇱🇻
The Family Physician's Practice of Dr. Maija Kozlovska, Salaspils, Latvia
🇨🇦Hamilton Medical Research Group, Hamilton, Ontario, Canada
🇮🇪Connolly Hospital, Dublin, Ireland
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT04396106
- Locations
- 🇺🇦
Atea Study Site, Kyiv, Ukraine
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Registration Number
- NCT04309734
- Locations
- 🇧🇪
Clinical Trial Site, Antwerp, Belgium
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04019717
- Locations
- 🇲🇩
Clinical Trial Site, Chisinau, Moldova, Republic of
Study of AT-527 in Healthy and HCV-Infected Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT03219957
- Locations
- 🇲🇩
Clinical Trial Site, Chisinau, Moldova, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath